tirzepatide news october 2025 FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly 🎉 BIG NEWS: Eli Lilly

The statements have not been approved by the European Food Safety Authority or the European Commission

A practical tip that experienced researchers share is to only reconstitute what you can use within 30 days

The FDA also says telehealth companies are advertising drug products branded with the telehealth firms name or trademark without qualification, implying they are the compounder

The medications are also being studied in late stages of clinical development for chronic kidney disease and non-alcoholic fatty liver disease, where theyve shown promise

USE IN PATIENTS WITH RENAL IMPAIRMENT Two trials are available examining the impact of renal impairment on oral semaglutide safety, tolerability, and pharmacokinetics